Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome

Journal of Internal Medicine

Volumn 277, Issue 3, 2015, Pages 331-342

  Angelin, Bo ^a,b   Kristensen, Jens D ^c   Eriksson, Mats ^a,b   Carlsson, Bo ^c   Klein, Irwin ^d   Olsson, Anders G ^e   Chester Ridgway, E ^f   Ladenson, Paul W ^g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Karo Bio   (Sweden)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Stockholm Heart Center   (Sweden)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Hypercholesterolaemia; Lipoprotein; Liver; Thyroid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILIRUBIN; EPROTIROME; LIOTHYRONINE; LIPOPROTEIN A; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; 3-((3,5-DIBROMO-4-(4-HYDROXY-3-(1-METHYLETHYL)PHENOXY)PHENYL)AMINO)-3-OXOPROPANOIC ACID; ANILIDE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE DISEASE; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPHONIA; EYE SWELLING; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; HYPERLIPIDEMIA; INCREASED APPETITE; INFLUENZA; LIOTHYRONINE BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; BONE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; HEART RATE; METABOLISM; MIDDLE AGED;

ANILIDES; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BLOOD PRESSURE; BONE AND BONES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MALE; MIDDLE AGED; THYROTROPIN; TRIGLYCERIDES; TRIIODOTHYRONINE;

EID: 84923080277     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12261     Document Type: Article

References (35)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in14 randomised trials of statins. Lancet 2005; 366: 1267-78.
2. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Asessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
3. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk and Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375: 1634-9.
4. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-23.
5. Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006; 113: 1140-50.
6. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 1972; 220: 996-1008.
7. Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010; 21: 499-506.
8. Thompson GR, Soutar AK, Spengel FA, Jadhav SJ, Gavigan SJ, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 1981; 78: 2591-5.
9. Ness GC, Pendleton LC, Li YC, Chiang JY. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun 1990; 172: 1150-6.
10. Gullberg H, Rudling M, Saltó C, Forrest D, Angelin B, Vennström B. Requirement of hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 2002; 16: 1767-77.
11. Johansson L, Rudling M, Scanlan TS et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005; 102: 10297-302.
12. Tancevski I, Wehinger A, Demetz E et al. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res 2009; 50: 938-44.
13. Gälman C, Bonde Y, Matasconi M, Angelin B, Rudling M. Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology 2008; 134: 1127-36.
14. Smith SR, Lovejoy JC, Rood J. The effects of triiodothyronine on bone metabolism in healthy ambulatory men. Thyroid 2003; 13: 357-64.
15. Hill SR Jr, Varker SB, McNeil JH, Tingley JO, Hibbett LL. The metabolic effects of the acetic and propionic acid analogs of thyroxine and triiodothyronine. J Clin Invest 1960; 39: 523-33.
16. Sherman SI, Ringel MD, Smith MJ et al. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 1997; 82: 2153-8.
17. Berkenstam A, Kristensen J, Mellström K et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008; 105: 663-7.
18. Ladenson PW, Kristensen JD, Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906-16.
19. Third Report of the National Cholesterol Education Program (NCEP). Expert report on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143-421.
20. Erion MD, Cable EE, Ito BR et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007; 104: 15490-5.
21. Caron P, Bennet A, Barousse C, Nisula BC, Jouvet JP. Effects of hyperthyroidism on binding proteins for steroid hormones. Clin Encocrinol (Oxf) 1989; 31: 219-24.
22. Liu YY, Brent GA. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol Metab 2010; 21: 166-73.
23. Brunzell JD. Hypertriglyceridemia. N Engl J Med 2007; 357: 1009-17.
24. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010; 126: 314-45.
25. Cable EE, Finn PD, Stebbins JW et al. Reduction of hepatic stetosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009; 49: 407-17.
26. Prieur X, Huby T, Coste H et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005; 280: 27533-43.
27. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-28.
28. Gudnason V. Lipoprotein(a): a causal independent risk factor for coronary heart disease? Curr Opin Cardiol 2009; 24: 490-5.
29. Angelin B. Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 1997; 8: 337-41.
30. Ding EL, Song Y, Manson JE et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009; 361: 1152-63.
31. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009; 32: 541-6.
32. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010; 375: 735-42.
33. Sjouke B, Langslet G, Cesko R et al. Eprotirome in patients with familial hypercholesterolemia (the AKKA trial): a randomised, double-blind. Placebo-controlled phase 3 study. Lancet Diabetes Endocrinology 2014; http://dx.coi.org/10.1016/S2213-8587(14)70006-3.
34. Mostaza JM, De la Pedra C, Curiel MD, Peña R, Lahoz C. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women. Clin Chim Acta 2001; 308: 133-7.
35. Berry MJ, Kates AL, Larsen PR. Thyroid hormone regulates type I deiodinase messenger RNA in rat liver. Mol Endocrinol 1990; 4: 743-8.